Want to see NL:VVY full AI Analyst Report?
VVY Stock Chart & Stats
€1.12
€0.02(1.27%)
At close: 4:00 PM EDT
€1.12
€0.02(1.27%)
Day’s Range― - ―
52-Week Range€1.00 - €1.84
Previous CloseN/A
Volume2.70K
Average Volume (3M)18.70K
Market Cap
€31.10M
Enterprise Value€29.61M
Total Cash (Recent Filing)€2.45M
Total Debt (Recent Filing)€76.00K
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Dec 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding29,614,338
10 Day Avg. Volume20,264
30 Day Avg. Volume18,696
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)8.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal leverage reduces interest and refinancing pressure compared with a heavily indebted structure. This gives Vivoryon greater flexibility to allocate available capital toward clinical development, although the benefit is tempered by the company’s very small remaining equity base.
Lower Cash BurnThe substantial year-over-year improvement in operating cash burn suggests some progress in controlling cash use. If sustained, lower burn could extend financial runway and reduce the frequency or size of external funding needs while clinical programs continue.
Oral Clinical PipelineAn orally available lead candidate addresses a major neurodegenerative disease area and provides a defined clinical development focus. Positive clinical progress could create partnership, licensing, milestone, or royalty opportunities from the underlying platform.
Bears Say
No Recent RevenueThe absence of recent reported revenue means the business has not yet demonstrated commercial product monetization. Vivoryon therefore remains dependent on clinical progress and potential partnering or licensing outcomes to establish durable operating income.
Persistent Cash OutflowPersistent negative operating and free cash flow means current activities do not fund themselves. Continued clinical development will likely require external financing or further balance-sheet contraction, creating an ongoing constraint on strategic flexibility.
Shrinking Financial BaseThe sharp reduction in equity and total assets indicates that prior cash consumption has materially weakened the financial base. A smaller capital cushion reduces resilience, limits room for development spending, and increases dependence on future funding.
Vivoryon Therapeutics AG News
VVY FAQ
What was Vivoryon Therapeutics AG’s price range in the past 12 months?
Vivoryon Therapeutics AG lowest stock price was €1.00 and its highest was €1.84 in the past 12 months.
What is Vivoryon Therapeutics AG’s market cap?
Vivoryon Therapeutics AG’s market cap is €31.10M.
When is Vivoryon Therapeutics AG’s upcoming earnings report date?
Vivoryon Therapeutics AG’s upcoming earnings report date is Dec 03, 2026 which is in 53 days.
How were Vivoryon Therapeutics AG’s earnings last quarter?
Vivoryon Therapeutics AG released its earnings results on Aug 06, 2026. The company reported -€0.114 earnings per share for the quarter.
Is Vivoryon Therapeutics AG overvalued?
According to Wall Street analysts Vivoryon Therapeutics AG’s price is currently Overvalued.
Does Vivoryon Therapeutics AG pay dividends?
Vivoryon Therapeutics AG does not currently pay dividends.
What is Vivoryon Therapeutics AG’s EPS estimate?
Vivoryon Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivoryon Therapeutics AG have?
Vivoryon Therapeutics AG has 29,614,338 shares outstanding.
What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
Vivoryon Therapeutics AG reported an EPS of -€0.114 in its last earnings report. Following the earnings report the stock price went up 2.5%.
Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
Currently, no hedge funds are holding shares in NL:VVY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivoryon Therapeutics AG
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and preventing the formation of toxic pyroglutamate-Abeta (pGlu-Abeta). Its flagship compound, PQ912, a small molecule QC inhibitor, has successfully concluded Phase IIb clinical trials for both Alzheimer's disease and various cancer indications. Additionally, Vivoryon is advancing PQ1565, another small molecule (a glutaminyl-peptide cyclotransferase-like inhibitor), through preclinical development, specifically for cancer therapy. Beyond its small molecule programs, the company is also developing a monoclonal antibody designed to improve the clearance of pGlu-Abeta from the body. To bolster its research and development efforts, Vivoryon has forged several key partnerships, including collaborations with the University Medical Center Schleswig-Holstein for cancer immunotherapy discovery, Nordic Bioscience for the clinical progression of PQ912 in Alzheimer's, and the Fraunhofer Institute for cell therapy and immunology. Furthermore, a significant regional licensing agreement with Simcere Pharmaceutical Group Ltd. aims to develop and commercialize treatments for Alzheimer's disease by targeting the neurotoxic amyloid species N3pE (pGlu-Abeta). Established in 1997, Vivoryon Therapeutics N.V. maintains its headquarters in Halle, Germany.
Technical Analysis
Pharming Group
―
Avantium N.V.
―
Corbion NV
―
Lakefront Biotherapeutics NV
―
DSM-Firmenich AG
―